![COVID-19 vaccine](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/COVID-19-vaccine-in-hands-375x225.jpg)
Following the
The EMA's human medicines committee (CHMP) assessed the data on the quality, safety and efficacy of the vaccine and recommended by consensus a formal conditional marketing authorisation be granted by the EC.
The vaccine works using messenger RNA (mRNA) which has instructions for making the coronavirus Spike (S) protein. This is a protein on the surface of the SARS-CoV-2 virus which the virus needs to enter the body's cells. When a person is given the vaccine, some of their cells will read the mRNA instructions and temporarily produce the S protein. The person's immune system will then recognise this protein as foreign and produce antibodies and activate T cells to attack it.
"This vaccine provides us with another tool to overcome the current emergency," said
A large blind clinical trial has shown that Moderna’s COVID-19 vaccine was effective at preventing COVID-19 in people from 18 years of age. The trial involved around 30,000 people in total. Half received the vaccine and half were given placebo injections. The vaccine is administered as two injections into the arm, 28 days apart.
Efficacy was calculated in around 28,000 people from 18 to 94 years of age
The trial also showed 90.9 percent efficacy in participants at risk of severe COVID-19, including those with chronic lung disease, heart disease, obesity, liver disease, diabetes or HIV infection. The high efficacy was also maintained across genders, racial and ethnic groups.
The post
© Russell Publishing Limited, 2021. All Rights Reserved., source